Mimicking phosphorylation at Ser-48 strongly reduces surface expression of human macrophage scavenger receptor class A: implications on cell motility  by Heider, Harald & Wintergerst, Eva S
Mimicking phosphorylation at Ser-48 strongly reduces surface expression
of human macrophage scavenger receptor class A:
implications on cell motility
Harald Heider*, Eva S. Wintergerst
Institute of Biochemistry, University of Basel, Vesalgasse 1, 4051 Basel, Switzerland
Received 1 May 2001; revised 3 August 2001; accepted 8 August 2001
First published online 24 August 2001
Edited by Masayuki Miyasaka
Abstract The role of human macrophage scavenger receptor A1
(SRA1) in the development of atherosclerotic lesions is still
scarcely defined. Substituting serine 48 in human SRA1 by an
aspartate demonstrated that (1) surface expression of the
mutated receptor was 13-fold decreased; (2) the amount of
cell-associated Texas red-labeled acetylated low density lipopro-
tein (LDL) in mutant receptor-expressing cells was almost three-
fold reduced; (3) the migration of mutant receptor-transfected
cells towards surfaces coated with oxidized LDL decreased by
almost 60% compared to cells that were transfected with the wild
type receptor. Phosphorylation of the cytoplasmic part of SRA1
may help to modulate the residence time of macrophages in
atherosclerotic lesions. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
Key words: Scavenger receptor; Macrophage;
Acetylated low density lipoprotein; Cell motility;
Surface expression
1. Introduction
Macrophage scavenger receptor A (SRA) is one of the best
characterized receptors of the continuously growing family of
scavenger receptors. Its primary sequence was already deter-
mined in 1990 [1]. But the role of SRA1 in foam cell forma-
tion is still not well understood. Apolipoprotein E and SRA1
double knockout mice develop larger lesions upon a high
cholesterol diet, according to a recent study [2], whereas in
another publication the opposite e¡ect was described [3].
Overexpression of SRA1 in a mouse model yielded enhanced
foam cell formation in vitro [4] but reduced atherosclerotic
lesions in vivo [5], indicating that SRA1, despite its ability
to mediate uptake of modi¢ed lipoproteins, is involved in
antiatherogenic processes. The contribution of SRA to uptake
of oxidized low density lipoprotein (OxLDL), a modi¢ed lipo-
protein with a variety of proatherogenic properties [6], ac-
counts for approximately 30% of total uptake, indicating
that other scavenger receptors are involved in intracellular
lipid accumulation [7].
SRA also plays an important role in cell adhesion and in
the establishment and maintenance of cell^cell contact [8].
However, it is not clear how the adhesion properties of
SRA contribute to atherosclerotic lesion development. It has
been proposed that modulation of adhesion may in£uence the
residence time of cells at sites of cellular activation, e.g. in
atherosclerotic plaques [9]. Unfortunately, there exist no clear
data showing how adhesion properties could be changed. Re-
cently, Fong and Le [10] found evidence that preventing phos-
phorylation of Ser-49 (corresponds to Ser-48 in human SRA1)
in mouse SRA1 reduces acetylated LDL (AcLDL) internal-
ization rates, suggesting that posttranslational modi¢cation
might be a mechanism to modulate scavenger receptor func-
tionality.
Here we found evidence that mimicking phosphorylation at
serine 48 by an aspartate in human macrophage SRA1 de-
creases surface expression, lipoprotein binding and uptake,
and the mobility of cells expressing the mutated receptor.
Implications for the anti-atherosclerotic properties of SRA1
are discussed.
2. Materials and methods
2.1. Cells and transfections
COS-7 cells (ATCC CRL-1651) were cultured as described [11].
One day prior to transfection, cells were seeded at 40% con£uence
into either 12-well plates on coverslips for £uorescence microscopy or
directly into six-well plates for lipid analysis, or biotinylation assays,
respectively. On the day of transfection, cell density was routinely
5U104 cells/cm2. Lipid-mediated transfections with FuGENE1
(Roche Molecular Biochemicals, Rotkreuz, Switzerland) were carried
out as described [11].
2.2. RT-PCR and construction of the plasmids
Total cellular RNA from human monocyte-derived macrophages
cultured for 4 days in RPMI and 5% heat-inactivated human serum
was extracted with the RNeasy kit from Qiagen (Qiagen, Basel, Swit-
zerland) and reverse transcribed using SuperScript II RNase3 Reverse
Transcriptase1 and oligo(dT) primers (Life Technologies AG, Basel,
Switzerland) according to the instructions of the manufacturer. The
resulting cDNA was ampli¢ed in a PCRsprint thermocycler (Catalys
AG, Wallisellen, Switzerland) using the sense primer 5P-CCC AAG
CTT GGA TGG AGC AGT GGG ATC ACT TTC AC-3P and the
antisense primer 5P-GGG GTA CCG CAT TAT AAA GTG CAA
GTG ACT CCA GCA-3P. The restriction sites used for cloning are
shown in bold. PCR bands corresponding to the expected size for
SRA1 were excised and puri¢ed using the NucleoSpin Extract kit
(Macherey-Nagel, Du«ren, Germany). The puri¢ed PCR product was
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cut and ligated into the identically cut vector pEGFP-C1 (Clontech
Laboratories, Basel, Switzerland). Clones were analyzed by automated
sequencing (Applied Biosystems, model 377 DNA sequencer).
2.3. Site-directed mutagenesis
The plasmid encoding the correct fusion protein (referred to as
EGFP/SRA1) was mutagenized using the Stratagene Quickchange1
site-directed mutagenesis kit according to the instructions supplied by
the manufacturer. The sense and antisense mutagenesis primers
(sense: 5P-CCTTCAAGAGAAACTGAAGGACTTCAAAGCTGC-
AC-3P, antisense: 5P-GTGCAGCTTTGAAGTCCTTCAGTTTCTC-
TTGAAGG-3P, altered nucleotides are shown in bold letters) were
chosen to exchange the Ser-48 codon TCC to the aspartate codon
GAC. Plasmids containing the correct mutation were identi¢ed by
automated sequencing. We designated this plasmid EGFP/
SRA1(S48D).
2.4. LDL isolation, modi¢cation and Texas red labeling
Human LDL was isolated under lipopolysaccharide-free conditions
by discontinuous gradient density and £otation ultracentrifugation in
a TL-100 ultracentrifuge (Beckman Instruments, Fullerton, CA, USA)
and a TLA-100.4 ¢xed angle rotor as described previously [12].
AcLDL and OxLDL were prepared according to [13]. Protein con-
centrations of all LDL solutions were determined with bicinchoninic
acid (Pierce, Boston, MA, USA) with bovine serum albumin (BSA) as
a standard. AcLDL was labeled with Texas red (Molecular Probes,
Leiden, The Netherlands) according to the manufacturer’s instruc-
tions.
2.5. Fluorescence microscopy
Transfected cells used for microscopy were cultured on 15-mm
ethanol-washed glass coverslips (Merck Schweiz AG, Dietikon, Swit-
zerland) in 12-well Falcon plates (Becton Dickinson, Basel, Switzer-
land), and harvested 15 min after addition of Texas red-labeled
AcLDL (TR-AcLDL). They were washed twice with phosphate-bu¡-
ered saline (PBS) and ¢xed in 4% paraformaldehyde for 10 min at
room temperature. Fixed cells were washed twice in PBS and mounted
in Mowiol (Hoechst, Frankfurt, Germany), containing 1% n-propyl
gallate (Sigma-Aldrich, Buchs, Switzerland). Cells were examined us-
ing a Zeiss Axiophot microscope (Carl Zeiss AG, Feldbach, Switzer-
land), equipped with a Hamamatsu video imaging system and a Bio-
Point automated £uorescence ¢lter wheel (all video imaging
components including the software package were supplied by Paul
Bucher AG, Basel, Switzerland). Images were assembled with the
OpenLab software (Improvision, Coventry, UK).
2.6. Quantitation of the uptake of TR-AcLDL
The uptake of TR-AcLDL by transfected cells was calculated using
the ROI (region of interest) measurement tool of the OpenLab soft-
ware package. All images for quantitative measurements were re-
corded within one microscope session using identical exposure times
for all slides throughout one series of experiments. The exposure times
were chosen to be longer than 0.5 s in order to correct for £uctuations
of UV intensity. The outlines of green £uorescent cells of comparable
intensity were marked manually. Such a selected green £uorescence-
positive cell was de¢ned as one ROI. Then the appropriate excitation
¢lter for red £uorescence was set and total gray level intensity of red
£uorescence within single ROIs was recorded. Except for the vector
(approximately 45 cells), at least 100 £uorescent cells were measured
for each condition. Similar results were obtained in two independent
experiments.
2.7. SDS^PAGE and Western blots
SDS^PAGE was performed with the NuPAGE System from No-
vex1 (Frankfurt/Main, Germany). Proteins were transferred to Poly-
Screen1 PVDF transfer membranes (NEN Life Science, Zaventem,
Belgium) in blotting bu¡er (25 mM Tris, 192 mM glycine and 10%
methanol). First, blots were incubated in blocking bu¡er composed of
3% BSA (Fluka, Buchs, Switzerland) in PBS for 1 h at room temper-
ature before they were incubated for another 2 h in horseradish per-
oxidase^streptavidin conjugate (Zymed Laboratories, San Francisco,
CA, USA) diluted 1:2500 in blocking bu¡er. After four washing steps
in PBS plus 0.1% Tween 20 (PBST) detection was performed using the
enhanced chemiluminescence method (ECL1 system from Amersham,
UK). Bands were quanti¢ed densitometrically. Upon detection mem-
branes were reprobed with green £uorescent protein (GFP) antibod-
ies, followed by anti-mouse serum coupled to alkaline phosphatase.
Color detection was performed according to standard procedures.
2.8. Biotinylation and immunoprecipitation
Transfected cells were grown for 24 h in six-well Falcon plates
(Becton Dickinson, Basel, Switzerland), washed twice in 4 ml ice-
cold borate bu¡er (pH 8.3) and incubated for 30 min at room temper-
ature with 0.5 mg biotin-sulfo-N-hydroxysuccinimide with gentle ag-
itation. Then cells were washed twice in 4 ml ice-cold PBS and solu-
bilized in 300 Wl lysis bu¡er (PBST supplemented with 10 mM
ethylenediaminetetraacetic acid, 1 mM ethylene glycol-bis(L-amino-
ethyl ether)-N,N,NP,NP-tetraacetic acid, 1 mM Pefabloc0SC, 2 Wg/ml
aprotinin, 2 Wg/ml pepstatin and 2 Wg/ml leupeptin). Immunoprecipi-
tation was performed with monoclonal GFP antibodies (Roche Mo-
lecular Biochemicals, Rotkreuz, Switzerland) according to the proce-
dure described by Altin and Pagler [14].
2.9. Cell migration
Cell migration assays were performed in tissue culture-treated
Transwell1 plates (6.5 mm diameter, 10 Wm thickness, 8 Wm pores;
Costar, Cambridge, MA, USA). Half of the wells were coated on the
upper side of the membrane, the other half of the wells were coated on
the underside. For coating we used either 10 Wg/ml rat tail collagen
type I (Upstate Biotechnology, Lake Placid, NY, USA), or 20 Wg/ml
OxLDL for 2 h at room temperature followed by a washing step in
PBS. 40 000 transfected cells were added into the upper chambers 4 h
after transfection. Cells were allowed to migrate to the underside of
the membrane during 20 h. Subsequently non-migrating cells in half
of the wells were removed with a cotton swab. The number of all
green £uorescent cells was counted with an inverted microscope using
a 20U objective (Nikon, Ku«snacht, Switzerland). We subsequently
calculated the relative amount of migrating cells by dividing the num-
ber of migratory £uorescent cells by the number of all £uorescent
cells, migrating and non-migrating. We counted at least 400 cells in
either of two independent wells.
3. Results
3.1. Plasma membrane expression of SRA1 in EGFP/SRA1-
and EGFP/SRA1(S48D)-transfected cells
First we investigated whether mutation of Ser-48 to aspar-
tate in human SRA1 in£uences surface expression. In order to
e⁄ciently monitor expression we fused wild type and mutant
receptor to the C-terminal end of EGFP. Then we transfected
COS-7 cells with both constructs, and biotinylated all proteins
at the surface of the cells as described in Section 2. Immuno-
precipitation of fusion proteins with GFP-speci¢c antiserum
revealed that no biotinylated proteins in vector-transfected
cells could be isolated (Fig. 1A, ‘EGFP’). In contrast, massive
amounts of biotinylated proteins were precipitated in cells
transfected with EGFP/SRA1 (Fig. 1A, ‘SRA1’). Two bands
appeared, but only the faster migrating band corresponds to
EGFP/SRA1 as shown by reprobing the blot with GFP anti-
serum (Fig. 1B, ‘SRA1’). Biotinylation analysis of cells trans-
fected with EGFP/SRA1(S48D) demonstrated that the surface
expression of this receptor is strongly reduced (Fig. 1A,
‘S48D’). The overall expression levels of the mutated receptor
increased more than two-fold (Fig. 1B, ‘S48D’), though the
amount of vector DNA used for transfection was identical for
both wild type and mutant receptor (1 Wg/well). Quanti¢cation
of the biotinylation of the EGFP^receptor fusion protein re-
vealed that cell surface expression of the phosphorylation site
mutant receptor was approximately ¢ve times lower compared
to the wild type receptor. Normalizing the expression levels of
the plasmids revealed that the surface expression of EGFP/
SRA1(S48D) was even 13 times lower than the surface expres-
sion of EGFP/SRA1 (Fig. 1C).
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In order to exclude that an unspeci¢c structural modi¢ca-
tion of the mutated receptor accounts for the reduced surface
expression, we treated the cells prior to biotinylation with
1 WM okadaic acid for 1 h. Okadaic acid is a well described
membrane-permeable inhibitor of serine/threonine phospha-
tases of type 1 and 2A [15]. This treatment resulted in a
marked attenuation of biotinylation of EGFP/SRA1 mole-
cules. Less than 40% of the molecules labeled in untreated
cells were biotinylated under these conditions (Fig. 1A,C,
‘SRA1+OA’), con¢rming that phosphorylation is involved in
surface expression of SRA1. The e⁄ciency of biotinylation
was hardly a¡ected by okadaic acid treatment of cells trans-
fected with the phosphorylation site mutant (Fig. 1A,
‘S48D+OA’). Fig. 1B shows that the expression pattern of
okadaic acid-treated, EGFP/SRA1- and EGFP/SRA1-
(S48D)-transfected cells is identical to the one seen in non-
treated cells.
3.2. Binding and uptake of TR-AcLDL
COS-7 cells were transfected with the EGFP vector alone
and incubated with TR-AcLDL. Double immuno£uorescence
showed that vector-transfected COS-7 cells could be easily
detected due to the bright cytoplasmic and nuclear green £uo-
rescence (Fig. 2A, GFP). These cells were neither able to bind
nor to take up TR-AcLDL (Fig. 2A, Texas red). COS-7 cells
that were transfected with the EGFP/SRA1 fusion construct
showed a punctate to reticular green £uorescent staining pat-
tern in the cytoplasm with a concentration of the green £uo-
rescence in a polarized, perinuclear region (Fig. 2B, GFP). At
4‡C TR-AcLDL staining was concentrated at the plasma
membrane region and overlapped with green £uorescence in
these areas (Fig. 2B, Texas red and overlay). At 37‡C the cells
took up the £uorescently labeled modi¢ed lipoprotein already
within 15 min of incubation (Fig. 2B, Texas red). The staining
patterns of red and green £uorescence partially colocalized
(Fig. 2B, overlay). COS-7 cells that were transfected with
the mutated receptor (Fig. 2C) showed a weaker binding of
TR-AcLDL at 4‡C. In addition, the amount of TR-AcLDL
internalized at 37‡C appears to be smaller than in cells trans-
fected with the wild type receptor.
The qualitative data described above were con¢rmed by
quantitative measurements of cell-associated TR-AcLDL.
We calculated the amount of Texas red £uorescence associ-
ated with transfected cells as described in Section 2. At 4‡C,
cells transfected with EGFP/SRA1 bound almost three times
more TR-AcLDL than EGFP/SRA1(S48D)-transfected cells
(Fig. 3, white bars). Normalizing to the higher rate of surface
expression of the wild type receptor-transfected cells (5.2-fold)
and subtracting the value obtained for binding to vector-
transfected cells (0.12), we calculated that binding of TR-
AcLDL to the mutant receptor at 4‡C reached 90% of the
amount that bound to the wild type receptor. At 37‡C, wild
type transfected cells bound and/or took up almost three times
more TR-AcLDL than cells that expressed the phosphoryla-
tion site mutant (Fig. 3, black bars). Normalizing these values
as described above shows that the mutant receptor at the cell
surface takes up TR-AcLDL even more e⁄ciently than the
wild type receptor. Obviously, the uptake underlies further
regulatory mechanisms.
3.3. Cell motility of the transfected cells
In a next step, we analyzed the migration behavior of trans-
fected cells. The cells were allowed to attach to and spread
and migrate on porous polycarbonate membranes that were
coated on the upper or lower side of the membrane with either
collagen type I or OxLDL. On collagen-coated surfaces,
EGFP-, EGFP/SRA1- and EGFP/SRA1(S48D)-expressing
cells all showed similar cell migration behavior, irrespective
of whether the membranes were coated on their undersides
or on their upper sides. The overall di¡erence in the number
of migrating cells on collagen-coated surfaces was less than
8% (data not shown). On membranes coated either on the
upper side (Fig. 4, white bars) or on the lower side (Fig. 4,
black bars) with OxLDL, the majority of cells expressing only
the EGFP vector remained on the upper side of the mem-
brane. In contrast, more than 70% of the cells expressing
the wild type receptor moved to the lower side of the mem-
brane, provided this side was coated with OxLDL. If the
upper side was coated with OxLDL, only around 33% of
the cells transmigrated, whereas approximately 45% of the
mutant receptor-transfected cells transmigrated, irrespective
of which side was coated with OxLDL.
4. Discussion
First we showed that, at the cell surface, the steady-state
expression level of the phosphorylation site mutant is mark-
Fig. 1. Plasma membrane expression of SRA1 in transfected COS-7
cells. COS-7 cells were transfected with the EGFP vector (‘EGFP’),
with EGFP/SRA1 (‘SRA1’) as well as EGFP/SRA1(S48D) (‘S48D’).
After 24 h membrane proteins of the living cells were biotinylated.
Then the cells were lysed and fusion proteins isolated by immuno-
precipitation with GFP antiserum. The precipitated proteins were
separated on SDS^PAGE and blotted onto PVDF membranes. The
resulting blots were incubated with horseradish peroxidase-coupled
streptavidin and bands were visualized with chemiluminescence (A).
Then blots were washed and reprobed with GFP antiserum, fol-
lowed by mouse antiserum coupled to alkaline phosphatase. Bands
were visualized with the appropriate color reaction (B). In C the
amount of biotinylated protein was normalized to the amount of fu-
sion protein expressed.
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edly decreased. A substantial decrease in surface expression
was also observed in cells that were transfected with the wild
type receptor and that were treated with a serine/threonine
phosphatase inhibitor. It has been shown recently that recy-
cling of the T cell receptor back to the membrane was crit-
ically dependent on dephosphorylation of one of its subunits
[16]. The authors present evidence that a serine/threonine
phosphatase of type II is involved in dephosphorylation of
the receptor subunit and its return to the cell surface. Simi-
larly, Innamorati et al. [17] present evidence that vasopressin
V2 receptor recycling includes a step regulated by dephos-
phorylation of a speci¢c C-terminal domain. Our data from
okadaic acid treatment as well as the data obtained with the
mutated receptor are in agreement with recycling mechanisms
that are critically dependent on dephosphorylation of human
SRA1.
Reduction of surface expression of SRA1 impaired ligand
binding and/or uptake. We measured a substantial decrease in
cell-associated TR-AcLDL in cells transfected with the phos-
phorylation site mutant. Interestingly, Fong and Le [10] pre-
Fig. 2. Immuno£uorescence analysis of TR-AcLDL uptake by transiently transfected COS-7 cells. COS-7 cells were transfected with the EGFP
vector (A), EGFP/SRA1 (B) or EGFP/SRA1(S48D) (C). After 24 h of growth on glass coverslips in Iscove’s modi¢ed Dulbecco’s medium sup-
plemented with 10% fetal calf serum, cells were incubated with TR-AcLDL (50 Wg/ml) for the times indicated at either 4‡C or 37‡C. Then cells
were ¢xed and analyzed by £uorescence microscopy using the appropriate ¢lter sets for GFP and Texas red. The overlay of the corresponding
images is shown in column 3 (‘overlay’).
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viously demonstrated that COS cells transfected with mouse
SRA1 in which serine 49 (which corresponds to serine 48 in
human SRA1) was inactivated by replacing it with an alanine
also display signi¢cantly decreased amounts of cell-associated
AcLDL. Obviously, both conditions, phosphorylation and de-
phosphorylation, result in a net decrease in ligand binding and
uptake. At ¢rst sight this seems contradictory, but Fong and
Le also showed that decrease of AcLDL binding and/or up-
take was counterbalanced by inactivating an additional puta-
tive phosphorylation site in the cytoplasmic part of SRA1,
suggesting that receptor function is critically dependent on
the pattern of phosphorylation of several sites. Complex phos-
phorylation patterns within the trimeric assembly of function-
al SRA1 may therefore be involved in ¢ne-tuning surface ex-
pression and ligand uptake via this receptor.
Further support for the involvement of additional molecule
moieties in uptake of ligand comes from our observation that
mimicking phosphorylation indeed accelerates uptake of TR-
AcLDL, at least for those receptor molecules that reach the
cell surface.
In the meantime, Fong and coworkers also constructed the
Ser-49/Asp mutant of mouse SRA1. The amount of AcLDL
that was associated with COS cells transfected with this con-
struct dropped to less than 35% of the amount associated with
wild type receptor-transfected cells (Fong, personal communi-
cation). These numbers are in good agreement with the results
presented here.
In addition, it turned out that expression of SRA1 strongly
increased the mobility of cells towards OxLDL. Expression of
the phosphorylation site mutant increased cell motility, irre-
spective of whether the upper side or the lower side was
coated with OxLDL. Therefore, we suggest that chemotaxis
is operative in the case of the wild type receptor-transfected
cells, whereas the migration behavior of mutant receptor-
transfected cells indicates that their movement is best de-
scribed as chemokinesis.
It has been shown previously that AcLDL binding induces
tyrosine phosphorylation of a variety of intracellular proteins
in a macrophage-like cell line [18]. These phosphorylations
may trigger reorganization of the cytoskeleton, ¢nally leading
to mobility changes of the cells.
Increased expression of SRA1 at the cell surface could help
the cells to migrate more rapidly along a gradient of Ox-LDL,
thereby ingesting the modi¢ed lipoprotein and other in£am-
matory agents which reside in an atherosclerotic plaque. This
would shorten the exposure time of the SRA-expressing cells
and neighboring cells to in£ammatory signals and might ex-
plain why SRA1 knockout mice in a APOE3 Leiden trans-
genic mouse background develop more severe lesions when
fed an atherogenic diet than APOE3 Leiden mice fed identi-
cally [2]. It could also explain the observation of de Winther
and coworkers [5] that SRA1 overexpression in LDL receptor-
de¢cient transgenic mice fed a high fat diet actually reduces
atherosclerosis.
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Fig. 4. Mobility of SRA1-expressing COS-7 cells on membranes
coated with rat tail collagen or human OxLDL. Transfected cells
were allowed to attach to and spread and migrate for 20 h on po-
rous polycarbonate membranes that were coated on their upper
sides (white bars) or on their lower sides (black bars) with 20 Wg/ml
OxLDL. Represented here is the percentage of cells that migrated
to the underside of the membranes. For each condition, we counted
at least 400 cells in either of two independent wells.
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